TDR compared to ACDF for ASD | ||||||
---|---|---|---|---|---|---|
Patient or population: patients with ASD Settings: Intervention: TDR Comparison: ACDF | ||||||
Outcomes | Illustrative comparative risksa (95% CI) | Relative effect (95% CI) | No of participants (studies) | Quality of the evidence (GRADE) | Comments | |
Assumed risk | Corresponding risk | |||||
ACDF | TDR | |||||
ASD Follow-up: 24–84 months | Study population | OR 0.6 (0.49 to 0.73) | 2632 (11 studies) | ⊕ ⊕ ⊕⊝ moderate | ||
256 per 1000 | 171 per 1000 (144 to 201) | |||||
Moderate | ||||||
GRADE Working group grades of evidence | ||||||
High quality: Further research is very unlikely to change our confidence in the estimate of effect. | ||||||
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. | ||||||
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. | ||||||
Very low quality: We are very uncertain about the estimate. |